Clinical Research (Field)

British pharma giant announces substantial manufacturing and R&D expansion as industry responds to reshoring pressures

Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.

The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.

The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.

Scientists from Uppsala University and KTH Royal Institute of Technology have developed a new type of antibody that could lead to safer and more effective cancer treatments. 

The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. 

Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics.  

American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill. 

In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.